CTOs on the Move

The Simply Good Foods Company

www.thesimplygoodfoodscompany.com

 
The Simply Good Foods Company, or “Simply Good Foods”, is the company created by the business combination of Conyers Park Acquisition Corp. and Atkins Nutritionals, Inc. Simply Good Foods will look to expand its platform through investment opportunities in the snacking space and broader food category. Over time, Simply Good Foods will look to become a portfolio of brands that bring simple goodness, happiness and positive experiences to consumers and their families. Simply Good Foods` common stock and warrants are listed on the NASDAQ stock exchange under the symbols “SMPL” and “SMPL.W”, respectively.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Safe Ride Services

Safe Ride Services is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vitruvias Therapeutics

Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.

Vesta Healthcare

At Vesta Healthcare, we believe that improving quality of life is possible when we connect technology with clinical expertise, and caregivers and care recipients with the care team.

Portage Path Behavorial Health

Portage Path Behavorial Health is a Akron, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.